Clinical Trial Search

Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35

Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl

Primary: Mean Blood Glucose of All Readings — 157.2; 181.8 mg/dL

Primary: Hospital Length of Stay — 7; 8 days

Primary: Mortality — 36 mortality rate

Primary: Serum Blood Glucose Concentrations — 101; 137; 140; 141 mg/dl

Primary: Insulin Sensitivity — 1835.4; 1846.0 ratio without units — p=.983

Primary: Change From Baseline in Insulin Sensitivity — 3.2; 0.4 microUnits/mL — p=0.08

Primary: Glycemic Control — 10.7; 10.9 mmol/L — p=0.677

Primary: Hemoglobin A1C at 4 Weeks — 10.5; 11.1 percentage of glycosylated hemoglobin

Primary: Number of Patients With Hyperglycemia in the Intensive Care Unit (ICU) — 76; 68 Participants

Primary: Prevalence of Hyperglycemia in the Elective Orthopedic Population — 140 patients

Primary: Time to Achieve Glycemic Control — 225 Minutes

Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L

Primary: Measurement of the Change in Plasma Glucose (mg/dL): Study 1 — -29; -17 mg/dl

Primary: Mean Blood Glucose Concentration After First Day of Treatment — 9.5; 9.4 mmol/L

Primary: Differences in Glycemic Control as Measured by Time Reach Glycemic Control for Each Treatment Group. — 5; 10.1; 7.7 Time to reach glycemic control in hours — p=<0.05

Primary: Median Glucose Values From Steady State Through 48 Hours or Until Discharge. — 132; 127; 105 mg/dL — p=<0.001

Primary: Plasmatic Glucose Levels (mg/dl). — 80; 82; 114; 111 mg/dl — p=0.38

Primary: Glucagon Counterregulation to Hypoglycemia — 16.0; 16.5 pmol/l

Primary: Mean Daily Blood Glucose Concentration Inpatient — 177.1; 154.1; 166.1 mg/dL

Primary: Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight — 5.5; 2.4; 2.7 kg — p=<0.05

Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035

Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants

Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05

Primary: Hospital Length of Stay — 7; 8 days

Primary: Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours — 13.0; 22.5 hours

Primary: The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment. — 5.35; 5.72 Hypoglycaemic episodes

Primary: Insulin Secretion — 56766 pmol/l * 90 minutes

Primary: Glycemic Control at Hospital Discharge and 6 Months Follow up — 8.3; 8.4; 7.13; 7.68 % (mmol/mol)